Initial treatment for extensive chronic GVHD at diagnosis, according to transplant arm
| . | No. of patients (%) . | |
|---|---|---|
| BMT (n = 32) . | PBSCT (n = 39) . | |
| None | 1 (3) | 0 (0) |
| Topical corticosteroids (mouth and vagina) | 0 (0) | 1 (2.6) |
| Cyclosporine | 1 (3) | 6 (15) |
| Prednisone | 2 (6.5) | 0 (0) |
| Mycophenolate mofetil (MMF) | 0 (0) | 1 (2.6) |
| Prednisone plus cyclosporine | 25 (78) | 26 (67) |
| Prednisone plus tacrolimus | 1 (3) | 1 (2.6) |
| Prednisone plus mycophenolate mofetil | 0 (0) | 2 (5) |
| Prednisone plus cyclosporine plus thalidomide | 2 (6.5) | 1 (2.6) |
| Prednisone plus tacrolimus plus MMF | 0 (0) | 1 (2.6) |
| . | No. of patients (%) . | |
|---|---|---|
| BMT (n = 32) . | PBSCT (n = 39) . | |
| None | 1 (3) | 0 (0) |
| Topical corticosteroids (mouth and vagina) | 0 (0) | 1 (2.6) |
| Cyclosporine | 1 (3) | 6 (15) |
| Prednisone | 2 (6.5) | 0 (0) |
| Mycophenolate mofetil (MMF) | 0 (0) | 1 (2.6) |
| Prednisone plus cyclosporine | 25 (78) | 26 (67) |
| Prednisone plus tacrolimus | 1 (3) | 1 (2.6) |
| Prednisone plus mycophenolate mofetil | 0 (0) | 2 (5) |
| Prednisone plus cyclosporine plus thalidomide | 2 (6.5) | 1 (2.6) |
| Prednisone plus tacrolimus plus MMF | 0 (0) | 1 (2.6) |